This is a working overview of GW501516, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-10 and is reviewed periodically as new material appears.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
=== Activation by cellular stress === p53 is activated in response to a range of cellular stressors, including DNA damage (for example from ultraviolet or ionizing radiation), osmotic shock, ribonucleotide depletion, oncogene activation, and some viral infections. Activation involves stabilization of the p53 protein, resulting in its accumulation in the nucleus, and regulatory changes that promote sequence-specific DNA binding and transcriptional activation of target genes. These processes are initiated in part by phosphorylation of residues in the N-terminal transactivation domain by stress-activated kinases. Phosphorylation of sites within the Mdm2-binding region (for example Ser20) can reduce binding to MDM2 and thereby decrease ubiquitin-mediated degradation of p53.
=== Blocking of L-type calcium channels === Because the presence of calcium in the cytosol is required for muscle contraction, blockers of calcium channels prevent the muscles from building tension. Blockers of the L-type calcium channels, which occur in cardiac and smooth muscles, thus act as smooth muscle relaxants and inhibitors of cardiac contractions. Common blockers of L-type calcium channels are 1,4-dihydropyridines, which are used in treatment of cardiovascular diseases. Because of their activity as a relaxant, they can relax smooth muscles surrounding blood vessels, thus widening them and lowering the blood pressure.
== Awards and honors == 1976–1981 - N.I.H. Research Career Development Award 1975, 1992 - Kaiser Permanente Award for Excellence in Teaching 1996–1997 - President, Biophysical Society 1997 - Distinguished Lecturer, Beckman Center, University of Illinois at Urbana-Champaign 1999 - Distinguished Service Award, Biophysical Society 2000 - Athalie Clarke Research Achievement Award, Outstanding Researcher, UCI College of Medicine 2001 - Fellow, Biophysical Society 2002 - César Milstein Plenary Lecture, XIVth International Biophysics Congress 2006 - Keynote Lecture, Gordon Research Conference on Biopolymers 2008 - Ph.D. honoris causa, Stockholm University 2009 - Avanti Award in Lipids, Biophysical Society 2009 - Bioengineering Distinguished Speaker, University of California at Riverside 2010 - Matrone Distinguished Lecture in Biochemistry, North Carolina State University 2010 - Cátedra de Investigación Científica, Autonomous University of San Luis Potosí 2010 - Frederic M. Richards Lecture, Yale 2011 - O'Malley Lectures in Chemical Biology, Boston College 2014 - Carl Brändén Award, The Protein Society 2016 - Fellow, Neutron Scattering Society of America 2018 - Fellow, American Association for the Advancement of Science 2019 - University of Kansas Newmark Award Lecture 2022 - UCI School of Medicine, Lifetime Research Achievement Award for Excellence in Basic Science research.
The second possibility, called AutomAb, requires only the signal of a single detector situated behind the first column. During initial loading, the signal increases, as more and more impurities make their way through the column. When the column is saturated with impurities and as long as the product is completely being captured on the column, the signal then remains constant. As soon as some of the product breaks through the column (compare above), the signal increases again. Thus, the timing and amount of product breakthrough can again be determined. Both iterations work equally well in theory. In practice, the requirement for two synced signals and the exposure of one detector to unpurified feed material, makes the DetaUV approach less reliable than AutomAb.
DNA sequence data shows that the mummies had Haplogroup R1a (Y-DNA) characteristic of western Eurasia in the area of East-Central Europe, Central Asia and the Indus Valley. This has created a stir in the Turkic-speaking Uighur population of the region, who claim the area has always belonged to their culture, while it was not until the 10th century that Uighurs are said by scholars to have moved to the region from Central Asia. American Sinologist Victor H. Mair claims that "the earliest mummies in the Tarim Basin were exclusively Caucasoid, or Europoid" with "east Asian migrants arriving in the eastern portions of the Tarim Basin around 3,000 years ago", while Mair also notes that it was not until 842 that the Uighur peoples settled in the area. Other mummified remains have been recovered from around the Tarim Basin at sites including Qäwrighul, Yanghai, Shengjindian, Shanpula (Sampul), Zaghunluq, and Qizilchoqa.
Sources: en.wikipedia.org
In August 2025, Newsom secured legislative approval of California Proposition 50, a state constitutional amendment to allow congressional redistricting. The goal was to switch seats from Republican to Democratic control in response to the 2025 Texas gerrymander that would add five new Republican seats. Voters approved the measure in November.
The rate of proteolysis may also depend on the physiological state of the organism, such as its hormonal state as well as nutritional status. In time of starvation, the rate of protein degradation increases.
An asymptomatic skin disorder of the vulval vestibule is vestibular papillomatosis, which is characterised by fine, pink projections from either the epithelium of the vulva or from the labia minora. Dermatoscopy can distinguish this condition from genital warts. A subtype of psoriasis, an autoimmune disease, is inverse psoriasis in which red patches can appear in the skin folds of the labia.
== References == Allen, Ira (1969) [1798]. The natural and political history of the State of Vermont, one of the United States of America. Charles E. Tuttle Company. ISBN 0-8048-0419-2. Cooper, Grace Rogers (1973). Thirteen Star Flags (PDF). Smithsonian Institution Press. Archived (PDF) from the original on 2022-10-09. Tuttle, Mrs. George F. (1909). 300 Years In The Champlain Valley. Saranac, NY: Daughters of the American Revolution. Van de Water, Frederic Franklyn (1974). The Reluctant Republic: Vermont 1724–1791. The Countryman Press. ISBN 0-914378-02-3. Shalhope, Robert. (1996). Bennington and the Green Mountain Boys: The Emergence of Liberal Democracy in Vermont, 1760-1850. Johns Hopkins University Press
Sources: en.wikipedia.org
In the article Cosmology and Civilizations published in 1997, Kardashev reiterates the need to carefully observe astronomical objects with strong radiation in order to detect supercivilizations. However, the discovery of a civilization at a stage of development similar to ours is unlikely. The existence of such supercivilizations is made possible by the fact that life on Earth is recent compared to the age of the Universe (8×109 years before the formation of the Solar System). He then examines the conditions for the appearance of life on cosmological time scales. Assuming the rate of evolution of life on Earth and considering the age of the Universe, it is reasonable to assume that a civilization could have reached our level of technological development in 6×109 years. Such civilizations can be observed in nearby regions, since the farther away we observe, the younger the objects are. Recent discoveries of sources of intense radiation deadly to life show that life could have flourished under cover for the time necessary for its appearance and maintenance. Another argument for the possibility of a very old supercivilization is that most of the objects that could be megastructures have not yet been discovered and mapped. In addition, 95% of the matter remains invisible or can only be inferred by the gravitational influence it produces. According to Kardashev, it is essential to focus our search tools on new objects radiating at a wavelength of a few microns to a few millimeters, and at a temperature of 3 to 300 K, which is characteristic of large structures of solid matter.
The β and γ phases are obtained by annealing the most stable α-Al2S3 phase at several hundred degrees Celsius. Compressing aluminum sulfide to 2–65 bar results in the δ phase where vacancies are arranged in a superlattice of tetragonal symmetry. Unlike Al2O3, in which the Al(III) centers occupy octahedral holes, the more expanded framework of Al2S3 stabilizes the Al(III) centers into one third of the tetrahedral holes of a hexagonally close-packed arrangement of the sulfide anions. At higher temperature, the Al(III) centers become randomized to give a "defect wurtzite" structure. And at still higher temperatures stabilize the γ-Al2S3 forms, with a structure akin to γ-Al2O3. Molecular derivatives of Al2S3 are not known. Mixed Al-S-Cl compounds are however known. Al2Se3 and Al2Te3 are also known.
=== The method === It has been shown through experimentation, that increasing the viral count (or level of activity) of a sample by a factor of 104 or 105 of the original will only change the virus removal/inactivation ratios by one order of magnitude . From this knowledge, spiking studies have been created in which the virus number (or level of activation) is increased or "spiked" by a factor of 104 or 105 of the original sample. This new high number or level of activity is then run through the process stream and purified. The number or level of activity is taken at the beginning and at the end of the process stream and used in the calculation of Reduction Factor.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.